Biomerica, Inc.
BMRANASDAQHealthcare● Active
$2.07
$-0.05(-2.36%)
Market Cap$6396857
P/E Ratio—
52W High$4.6
52W Low$1.87
Biomerica, Inc. (BMRA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BMRA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 13, 2026EPS Actual
-$0.44
Est. -$1.20 · +63.3%
Revenue
$0.00B
Est. $0.00B · -69.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 13, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 1-Quarter EPS Beat Streak
BMRA reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 27, 2026 | -$1.20 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | Apr 13, 2026 | -$1.20 | -$0.44 | +63.3% | $0.00B | $0.00B | -69.2% |
| ◌ Q2 FY2026 | Apr 9, 2026 | — | — | — | — | — | — |
| — Q1 FY2026 | Jan 14, 2026 | — | -$0.45 | — | $0.00B | — | — |
| — Q4 FY2025 | Oct 14, 2025 | — | $0.00 | — | $0.00B | — | — |
| — Q2 FY2025 | Apr 14, 2025 | — | -$0.48 | — | $0.00B | — | — |
| — Q1 FY2025 | Jan 14, 2025 | — | -$0.06 | — | $0.00B | — | — |
| — Q4 FY2024 | Oct 15, 2024 | — | -$0.08 | — | $0.00B | — | — |
Q3 FY2026
Aug 27, 2026
EPS Actual
—
EPS Est.
-$1.20
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 13, 2026Beat
EPS Actual
-$0.44
EPS Est.
-$1.20
EPS Surpr.
+63.3%
Revenue
$0.00B
Q2 FY2026
Apr 9, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2026
Jan 14, 2026
EPS Actual
-$0.45
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2025
Oct 14, 2025
EPS Actual
$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2025
Apr 14, 2025
EPS Actual
-$0.48
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2025
Jan 14, 2025
EPS Actual
-$0.06
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2024
Oct 15, 2024
EPS Actual
-$0.08
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2028 | $0.32 | $0.32 | $0.32 | 1 |
| Q2 FY2028 | $0.16 | $0.16 | $0.16 | 1 |
| Q1 FY2028 | $0.16 | $0.16 | $0.16 | 1 |
| Q4 FY2027 | $-0.16 | $-0.16 | $-0.16 | 1 |
| Q3 FY2027 | $-0.96 | $-0.96 | $-0.96 | 1 |
| Q2 FY2027 | $-0.80 | $-0.80 | $-0.80 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 13, 2026 | +63.3% | $2.13 | $2.08 | -2.35% |
| — Q1 FY2026 | Jan 14, 2026 | — | $2.71 | $2.70 | -0.37% |
| — Q4 FY2025 | Oct 14, 2025 | — | $2.80 | $2.88 | +2.86% |
| — Q2 FY2025 | Apr 14, 2025 | — | $4.28 | $4.42 | +3.27% |
| — Q1 FY2025 | Jan 14, 2025 | — | $2.57 | $2.62 | +1.95% |
| — Q4 FY2024 | Oct 15, 2024 | — | $2.72 | $2.57 | -5.51% |
| — Q2 FY2024 | Apr 12, 2024 | — | $6.49 | $6.62 | +2.00% |
| — Q1 FY2024 | Jan 16, 2024 | — | No price data | $7.65 | — |
Q2 FY2026-2.35%
Report Date
Apr 13, 2026
EPS Beat/Miss
+63.3%
Price Before
$2.13
Price After
$2.08
Q1 FY2026-0.37%
Report Date
Jan 14, 2026
EPS Beat/Miss
—
Price Before
$2.71
Price After
$2.70
Q4 FY2025+2.86%
Report Date
Oct 14, 2025
EPS Beat/Miss
—
Price Before
$2.80
Price After
$2.88
Q2 FY2025+3.27%
Report Date
Apr 14, 2025
EPS Beat/Miss
—
Price Before
$4.28
Price After
$4.42
Q1 FY2025+1.95%
Report Date
Jan 14, 2025
EPS Beat/Miss
—
Price Before
$2.57
Price After
$2.62
Q4 FY2024-5.51%
Report Date
Oct 15, 2024
EPS Beat/Miss
—
Price Before
$2.72
Price After
$2.57
Q2 FY2024+2.00%
Report Date
Apr 12, 2024
EPS Beat/Miss
—
Price Before
$6.49
Price After
$6.62
Q1 FY2024—
Report Date
Jan 16, 2024
EPS Beat/Miss
—
Price Before
—
Price After
$7.65
Avg Beat Reaction-2.35%
Beat Rate1 / 8 quarters
Largest Move-5.51% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BMRA ends December
Biomerica, Inc. (BMRA) most recently reported earnings on April 13, 2026 for Q2 FY2026, posting EPS of $-0.44 — beating the analyst consensus of $-1.20 by +63.3%. The next BMRA earnings date is expected around September 1, 2026.
Each quarter, investors track BMRA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BMRA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BMRA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BMRA earnings · 5 questionsBiomerica, Inc.'s next earnings report is expected around September 1, 2026. BMRA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BMRA historically reports after market close (AMC).
BMRA earnings datewhen is BMRA earningsBMRA next earnings datewhen does BMRA report earningsBMRA earnings calendar
▸ Source: FMP · Biomerica, Inc. SEC filings · US GAAP · Biomerica, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026